Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Vaxart, Inc. VXRT
$1.08
+$0.04 (3.85%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
145766766.00000000
-
week52high
4.62
-
week52low
0.56
-
Revenue
107000
-
P/E TTM
-1
-
Beta
0.79307900
-
EPS
-0.86000000
-
Last Dividend
12.18800000
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B. Riley Securities | Neutral | Neutral | 19 мая 2022 г. |
| Cantor Fitzgerald | Overweight | 02 ноя 2021 г. | |
| B. Riley Securities | Neutral | Buy | 30 июн 2021 г. |
| Jefferies | Buy | 24 июн 2021 г. | |
| Piper Sandler | Overweight | 11 июн 2021 г. | |
| Cantor Fitzgerald | Overweight | Overweight | 02 сент 2022 г. |
| B. Riley Securities | Neutral | Neutral | 19 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Watson W. Mark | A | 20000 | 20000 | 28 дек 2022 г. |
| Lee Phillip E | A | 412500 | 412500 | 16 дек 2022 г. |
| Lee Phillip E | A | 68750 | 68750 | 16 дек 2022 г. |
| HERON ELAINE J | A | 88448 | 88448 | 25 авг 2022 г. |
| HERON ELAINE J | A | 17644 | 14750 | 25 авг 2022 г. |
| Yedid Robert A. | D | 11115 | 4000 | 24 авг 2022 г. |
| Yedid Robert A. | D | 15115 | 4000 | 24 авг 2022 г. |
| Yedid Robert A. | D | 19115 | 18240 | 24 авг 2022 г. |
| Yedid Robert A. | D | 57700 | 8000 | 19 авг 2022 г. |
| Yedid Robert A. | D | 18240 | 18240 | 19 авг 2022 г. |
Новостная лента
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge
The Motley Fool
24 апр 2023 г. в 05:30
Novavax and Vaxart both were early favorites in the coronavirus vaccine race -- but the two companies fell behind. Since then, they've cut costs and shifted strategies.
Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus
GlobeNewsWire
17 мар 2023 г. в 08:00
Company to provide a detailed overview of its norovirus clinical program
Vaxart, Inc. (VXRT) Q4 2022 Earnings Call Transcript
Seeking Alpha
15 мар 2023 г. в 20:51
Vaxart, Inc. (NASDAQ:VXRT ) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Brant Biehn - Senior Vice President, Business Operations Andrei Floroiu - Chief Executive Officer James Cummings - Chief Medical Officer Sean Tucker - Founder & Chief Scientific Officer Phil Lee - Chief Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Mayank Mamtani - B. Riley Securities Operator Greetings.
Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15
GlobeNewsWire
08 мар 2023 г. в 16:05
Conference call to begin at 4:30 p.m. ET
Best Penny Stocks To Buy? 4 To Watch Before 2023
PennyStocks
29 дек 2022 г. в 14:07
Penny stocks to watch before next year. The post Best Penny Stocks To Buy?